Trump’s FDA nominee could renew scrutiny to abortion drug risk: pro-life org CEO

Here's the thing nobody wants to say out loud in polite company: mifepristone was approved in 2000 under an accelerated pathway meant for drugs treating serious or life-threatening illnesses, and pregnancy isn't a disease. That classification alone should have invited more scrutiny than it ever got. So when a pro-life advocate says Trump's FDA pick might finally "bring objectivity" to the drug's safety record, that's not a fringe complaint. It's a reasonable question about whether the agency did its homework twenty-five years ago and whether it's kept doing it since.

The FDA has loosened restrictions on this drug repeatedly over the past decade, dropping in-person dispensing requirements and expanding telehealth prescribing, all while the reporting requirements for complications got weaker, not stronger. You don't have to be plotting a national abortion ban to think that's worth a second look. Basic drug safety monitoring shouldn't be a partisan football, but it became one the moment anyone raised concerns, because raising concerns got treated as an attack on abortion access itself rather than a question about pharmacovigilance.

That's the real story here. An FDA that actually did rigorous, boring, apolitical safety review would either confirm the drug's record or it wouldn't, and either outcome should be fine. The fact that a new commissioner even looking into it is being framed as some kind of ideological crusade tells you how captured the conversation has been. Women deserve an agency that treats this like medicine, not a cause.